Literature DB >> 9048769

Altered calcium homeostasis in cells transformed by mitochondria from individuals with Parkinson's disease.

J P Sheehan1, R H Swerdlow, W D Parker, S W Miller, R E Davis, J B Tuttle.   

Abstract

Parkinson's disease may be linked to defects in mitochondrial function. Mitochondrially transformed cells (cybrids) were created from Parkinson's disease patients or disease-free controls. Parkinson's disease cybrids had 26% less complex I activity, but maintained comparable basal calcium and energy levels. Parkinson's disease cybrids recovered from a carbachol-induced increase in cytosolic calcium 53% more slowly than controls even with lanthanum and thapsigargin blockade. Inhibition of complex I with the Parkinson's disease-inducing metabolite 1-methyl-4-phenylpyridinium (MPP+) similarly reduced the rate of recovery after carbachol. This MPP(+)-induced reduction in recovery rates was much more pronounced in control cybrids than in Parkinson's disease cybrids. Parkinson's disease cybrids had less carbonyl cyanide m-chlorophenylhydrazone-releasable calcium. Bypassing complex I with succinate partially restored Parkinson's disease cybrid, and MPP+ suppressed control cybrid recovery rates. The subtle alteration in calcium homeostasis of Parkinson's disease cybrids may reflect an increased susceptibility to cell death under circumstances not ordinarily toxic.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9048769     DOI: 10.1046/j.1471-4159.1997.68031221.x

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  40 in total

Review 1.  The local control of cytosolic Ca2+ as a propagator of CNS communication--integration of mitochondrial transport mechanisms and cellular responses.

Authors:  P B Simpson
Journal:  J Bioenerg Biomembr       Date:  2000-02       Impact factor: 2.945

Review 2.  Mitochondrial dysfunction and oxidative damage in Alzheimer's and Parkinson's diseases and coenzyme Q10 as a potential treatment.

Authors:  M Flint Beal
Journal:  J Bioenerg Biomembr       Date:  2004-08       Impact factor: 2.945

Review 3.  The unresolved role of mitochondrial DNA in Parkinson's disease: An overview of published studies, their limitations, and future prospects.

Authors:  Amica C Müller-Nedebock; Rebecca R Brennan; Marianne Venter; Ilse S Pienaar; Francois H van der Westhuizen; Joanna L Elson; Owen A Ross; Soraya Bardien
Journal:  Neurochem Int       Date:  2019-06-21       Impact factor: 3.921

Review 4.  Mitochondrial dysfunction in the limelight of Parkinson's disease pathogenesis.

Authors:  Rebecca Banerjee; Anatoly A Starkov; M Flint Beal; Bobby Thomas
Journal:  Biochim Biophys Acta       Date:  2008-11-14

Review 5.  Endoplasmic reticulum Ca(2+) handling in excitable cells in health and disease.

Authors:  Grace E Stutzmann; Mark P Mattson
Journal:  Pharmacol Rev       Date:  2011-07-07       Impact factor: 25.468

6.  Calcium homeostasis and reactive oxygen species production in cells transformed by mitochondria from individuals with sporadic Alzheimer's disease.

Authors:  J P Sheehan; R H Swerdlow; S W Miller; R E Davis; J K Parks; W D Parker; J B Tuttle
Journal:  J Neurosci       Date:  1997-06-15       Impact factor: 6.167

7.  A cybrid cell model for the assessment of the link between mitochondrial deficits and sporadic Parkinson's disease.

Authors:  Daniela M Arduíno; A Raquel Esteves; Russell H Swerdlow; Sandra M Cardoso
Journal:  Methods Mol Biol       Date:  2015

Review 8.  Current perspective of mitochondrial biology in Parkinson's disease.

Authors:  Navneet Ammal Kaidery; Bobby Thomas
Journal:  Neurochem Int       Date:  2018-03-14       Impact factor: 3.921

9.  Microtubule depolymerization potentiates alpha-synuclein oligomerization.

Authors:  A Raquel Esteves; Daniela M Arduíno; Russell H Swerdlow; Catarina R Oliveira; Sandra M Cardoso
Journal:  Front Aging Neurosci       Date:  2010-01-04       Impact factor: 5.750

10.  Reduced axonal transport in Parkinson's disease cybrid neurites is restored by light therapy.

Authors:  Patricia A Trimmer; Kathleen M Schwartz; M Kathleen Borland; Luis De Taboada; Jackson Streeter; Uri Oron
Journal:  Mol Neurodegener       Date:  2009-06-17       Impact factor: 14.195

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.